Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 221 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016', provides an overview of the Pancreatic Ductal Adenocarcinoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Pancreatic Ductal Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Ductal Adenocarcinoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
- The report reviews pipeline therapeutics for Pancreatic Ductal Adenocarcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Pancreatic Ductal Adenocarcinoma therapeutics and enlists all their major and minor projects
- The report assesses Pancreatic Ductal Adenocarcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Pancreatic Ductal Adenocarcinoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Ductal Adenocarcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Pancreatic Ductal Adenocarcinoma Overview 10
Therapeutics Development 11
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview 11
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis 12
Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies 13
Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 15
Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pancreatic Ductal Adenocarcinoma - Products under Development by Companies 19
Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes 21
Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development 22
AbbVie Inc. 22
BerGenBio AS 23
Celgene Corporation 24
Clovis Oncology, Inc. 25
Coare Biotechnology, Inc. 26
Concordia Healthcare Corp. 27
FibroGen, Inc. 28
Forty Seven Inc. 29
Gilead Sciences, Inc. 30
Halozyme Therapeutics, Inc. 31
Immodulon Therapeutics Ltd. 32
Immunomedics, Inc. 33
Incuron, LLC 34
Incyte Corporation 35
Inovio Pharmaceuticals, Inc. 36
MedImmune, LLC 37
Medisyn Technologies, Inc. 38
Merck & Co., Inc. 39
Nerviano Medical Sciences S.r.l. 40
OncoMed Pharmaceuticals, Inc. 41
Oryx GmbH & Co. KG 42
Sillajen Biotherapeutics 43
Tara Immuno-Oncology Therapeutics LLC 44
Tokai Pharmaceuticals, Inc. 45
Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment 46
Assessment by Monotherapy Products 46
Assessment by Combination Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
BGB-324 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CBL-0137 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CBT-1111 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CBT-3112 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
demcizumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
durvalumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
durvalumab + tremelimumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
epacadostat - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
FG-3019 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
galeterone - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Hu-5F9G4 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ibrutinib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
idelalisib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
IMM-101 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
INCB-50465 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
INO-1400 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
ipafricept - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
itacitinib adipate - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
JX-929 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
MK-0752 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
MK-8628 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
momelotinib dihydrochloride - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
MRK-003 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
MT-477 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
NMSP-715 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Oligonucleotide to Inhibit IDO1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
paclitaxel albumin bound - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Parvoryx - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
PEGPH-20 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
porfimer sodium - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
PSL-001 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
rucaparib phosphate - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
sacituzumab - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
SBP-101 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
siG12D-LODER - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
vantictumab - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
Pancreatic Ductal Adenocarcinoma - Recent Pipeline Updates 136
Pancreatic Ductal Adenocarcinoma - Dormant Projects 214
Pancreatic Ductal Adenocarcinoma - Discontinued Products 215
Pancreatic Ductal Adenocarcinoma - Product Development Milestones 216
Featured News & Press Releases 216
Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer 216
Nov 09, 2015: Compelling Preclinical Data on Sun BioPharma's SBP-101 Presented at the 2015 American Pancreatic Association (APA) Annual Meeting 217
Oct 20, 2015: Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association Annual Meeting 218
Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer 218
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 220
Disclaimer 221

List of Tables

Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2016 11
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2016 21
Pancreatic Ductal Adenocarcinoma - Pipeline by AbbVie Inc., H1 2016 22
Pancreatic Ductal Adenocarcinoma - Pipeline by BerGenBio AS, H1 2016 23
Pancreatic Ductal Adenocarcinoma - Pipeline by Celgene Corporation, H1 2016 24
Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H1 2016 25
Pancreatic Ductal Adenocarcinoma - Pipeline by Coare Biotechnology, Inc., H1 2016 26
Pancreatic Ductal Adenocarcinoma - Pipeline by Concordia Healthcare Corp., H1 2016 27
Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H1 2016 28
Pancreatic Ductal Adenocarcinoma - Pipeline by Forty Seven Inc., H1 2016 29
Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H1 2016 30
Pancreatic Ductal Adenocarcinoma - Pipeline by Halozyme Therapeutics, Inc., H1 2016 31
Pancreatic Ductal Adenocarcinoma - Pipeline by Immodulon Therapeutics Ltd., H1 2016 32
Pancreatic Ductal Adenocarcinoma - Pipeline by Immunomedics, Inc., H1 2016 33
Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H1 2016 34
Pancreatic Ductal Adenocarcinoma - Pipeline by Incyte Corporation, H1 2016 35
Pancreatic Ductal Adenocarcinoma - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 36
Pancreatic Ductal Adenocarcinoma - Pipeline by MedImmune, LLC, H1 2016 37
Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H1 2016 38
Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H1 2016 39
Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H1 2016 40
Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 41
Pancreatic Ductal Adenocarcinoma - Pipeline by Oryx GmbH & Co. KG, H1 2016 42
Pancreatic Ductal Adenocarcinoma - Pipeline by Sillajen Biotherapeutics, H1 2016 43
Pancreatic Ductal Adenocarcinoma - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 44
Pancreatic Ductal Adenocarcinoma - Pipeline by Tokai Pharmaceuticals, Inc., H1 2016 45
Assessment by Monotherapy Products, H1 2016 46
Assessment by Combination Products, H1 2016 47
Number of Products by Stage and Target, H1 2016 49
Number of Products by Stage and Mechanism of Action, H1 2016 52
Number of Products by Stage and Route of Administration, H1 2016 54
Number of Products by Stage and Molecule Type, H1 2016 56
Pancreatic Ductal Adenocarcinoma Therapeutics - Recent Pipeline Updates, H1 2016 136
Pancreatic Ductal Adenocarcinoma - Dormant Projects, H1 2016 214
Pancreatic Ductal Adenocarcinoma - Discontinued Products, H1 2016 215